Проблема сосудистой коморбидности и пути ее решения

A research aim was estimation of therapeutic efficiency of «Mildronat» for patients with vascular comorbidity and chronic cerebrovascular pathology. The basic group of research was made by 30 patient’s with dyscirculatoria encephalopathy 1-3 stages, who is getting «Mildronat». A control group consisted of 30 patients representative to the basic group of research, that got standard therapy. The estimation of efficiency was conducted on the basis of dynamics of expressed of pathological symptoms of dynamics of indexes of scale of the asthenic state, of scale of quality of life of patient. «Mildronat» possesses the expressed antiasthenic effect, good bearableness, for certain improves the cognitive functions of patients and results in upgrading of life of patients with chronic cerebrovascular pathology. On results research «Mildronat» showed high therapeutic efficiency in treatment of patients with vascular comorbidity at all stages of chronic cerebrovascular pathology with a maximal effect on the early stages of disease. «Mildronat» can be drug of choice for patients with vascular comorbidity and to decide the problem of polypharmacy.